Announcements Trials
Browse Landscape

Phase

Phase 1 10Phase 2/3 3Phase 1/2 3Phase 3 2Phase 2 2Phase 4 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 77NIH 39INDUSTRY 2NETWORK 1INDIV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Tuberous Sclerosis 1Fibroma 1Facies 1Exanthema 1Erythema 1Breast Neoplasms 1

Interventions

Carboplatin 272Paclitaxel 267Gemcitabine 244Bevacizumab 225Cisplatin 216pembrolizumab 213Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 99Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 80Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Ipilimumab 64Bortezomib 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Sirolimus × Clear all
NCT03363763 2025-12-01

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

Aucta Pharmaceuticals, Inc

Phase 2 Terminated
24 enrolled 11 charts

Erythema, Exanthema, Fibroma, Tuberous Sclerosis, Facies

NCT06957379 2025-05-04

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Active not recruiting
78 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡